Skip to main content

Advertisement

SpringerLink
Log in

Trends in breast cancer incidence and mortality in the United States: implications for prevention

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

While debate continues regarding short-term changes in breast cancer incidence and the impact of screening on mortality, a long-term view of trends in incidence and mortality may better inform our understanding of the changing patterns of disease and ultimately guide in population-based prevention. Although many factors have influenced breast cancer incidence over the past seven decades, some have played more prominent roles at various times. Changing reproductive patterns, greater longevity, and post-menopausal hormone (estrogen + progesterone) were important in the steady increase before 1980, while mammographic screening, probably in conjunction with escalating combined estrogen + progesterone use, played dominant roles in the post-1980 surge. Accruing evidence also indicates that the rapid drop in 2003 was mostly due to a sharp decline in estrogen + progesterone use. The most paradoxical observation relates to the divergence in incidence and mortality trends most noticeable when mortality rates started to decline shortly after the surge in incidence rates started in 1980. In addition to the dynamic changes in risk factor profiles, the divergence reflects wider uptake of screening mammography, better characterization of tumor biology, and improvements in treatment. The rise in incidence rates over the past three decades is due to an increase in estrogen receptor positive (ER+) tumors, which respond favorably to treatment. On the other hand, the incidence of estrogen receptor negative (ER−) tumors, which respond poorly to hormonal therapy, has been decreasing for almost three decades. Furthermore, widespread adoption of screening mammography has led to tumors being diagnosed at earlier stages when treatment is effective and advances in treatment have ensured adoption of targeted and better tolerated therapies. To achieve long-term success in the primary prevention of breast cancer, a greater understanding of factors responsible for the decrease in ER− tumors is essential. In addition, improving the sensitivity of breast cancer screening to facilitate earlier detection of tumors with very aggressive phenotypes would go a long way in bridging the divergence between incidence and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. DeSantis C, Siegel R, Bandi P, Jemal A (2011) Breast cancer statistics, 2011. CA Cancer J Clin 61(6):409–418

    Article  PubMed  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29

    Article  PubMed  Google Scholar 

  3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90

    Article  PubMed  Google Scholar 

  4. Garfinkel L, Boring CC, Heath CW Jr (1994) Changing trends: an overview of breast cancer incidence and mortality. Cancer 74(1 Suppl):222–227

    Article  PubMed  CAS  Google Scholar 

  5. Anderson WF, Jatoi I, Devesa SS (2006) Assessing the impact of screening mammography: breast cancer incidence and mortality rates in Connecticut (1943–2002). Breast Cancer Res Treat 99(3):333–340

    Article  PubMed  Google Scholar 

  6. NCI (2012) The surveillance, epidemiology, and end results (SEER) cancer statistics review 1975–2007. National Cancer Institute, Bethesda

  7. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O’Meara ES, Buist DS, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A et al (2012) Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 156(9):635–648

    Article  PubMed  Google Scholar 

  8. Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399

    Google Scholar 

  9. Kelsey JL, Gammon MD, John EM (1993) Reproductive factors and breast cancer. Epidemiol Rev 15(1):36–47

    PubMed  CAS  Google Scholar 

  10. Helmrich SP, Shapiro S, Rosenberg L, Kaufman DW, Slone D, Bain C, Miettinen OS, Stolley PD, Rosenshein NB, Knapp RC et al (1983) Risk factors for breast cancer. Am J Epidemiol 117(1):35–45

    PubMed  CAS  Google Scholar 

  11. Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet 360(9328):187–195

    Google Scholar 

  12. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC (2011) Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 306(17):1884–1890

    Article  PubMed  CAS  Google Scholar 

  13. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE (2006) Adult weight change and risk of postmenopausal breast cancer. JAMA 296(2):193–201

    Article  PubMed  CAS  Google Scholar 

  14. Ginsburg OM, Martin LJ, Boyd NF (2008) Mammographic density, lobular involution, and risk of breast cancer. Br J Cancer 99(9):1369–1374

    Article  PubMed  CAS  Google Scholar 

  15. Warner E (2011) Clinical practice. Breast-cancer screening. N Engl J Med 365(11):1025–1032

    Article  PubMed  CAS  Google Scholar 

  16. American Cancer Society I (2012) Breast cancer facts and figures 2011–2012. ACS, Atlanta

  17. White E (1987) Projected changes in breast cancer incidence due to the trend toward delayed childbearing. Am J Public Health 77(4):495–497

    Article  PubMed  CAS  Google Scholar 

  18. Hamilton BE, Ventura SJ (2006) Fertility and abortion rates in the United States, 1960–2002. Int J Androl 29(1):34–45

    Article  PubMed  Google Scholar 

  19. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Munson ML (2003) Births: final data for 2002. Natl Vital Stat Rep 52(10):1–113

    PubMed  Google Scholar 

  20. Hamilton BE (2004) Reproduction rates for 1990–2002 and intrinsic rates for 2000–2001: United States. Natl Vital Stat Rep 52(17):1–12

    PubMed  Google Scholar 

  21. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96(3):218–228

    Article  PubMed  CAS  Google Scholar 

  22. Rosner B, Colditz GA (1996) Nurses’ health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst 88(6):359–364

    Article  PubMed  CAS  Google Scholar 

  23. Collaborative Group on Hormonal Factors in Breast Cancer (2012) Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 13(11):1141–1151

    Google Scholar 

  24. Demerath EW, Towne B, Chumlea WC, Sun SS, Czerwinski SA, Remsberg KE, Siervogel RM (2004) Recent decline in age at menarche: the Fels Longitudinal Study. Am J Hum Biol 16(4):453–457

    Article  PubMed  Google Scholar 

  25. Cole TJ (2000) Secular trends in growth. Proc Nutr Soc 59(2):317–324

    Article  PubMed  CAS  Google Scholar 

  26. Heck KE, Schoendorf KC, Ventura SJ, Kiely JL (1997) Delayed childbearing by education level in the United States, 1969–1994. Matern Child Health J 1(2):81–88

    Article  PubMed  CAS  Google Scholar 

  27. Key T, Appleby P, Barnes I, Reeves G (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–616

    Article  PubMed  CAS  Google Scholar 

  28. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332(24):1589–1593

    Article  PubMed  CAS  Google Scholar 

  29. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347(9017):1713–1727

    Google Scholar 

  30. Stefanick ML (2005) Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 118(Suppl 12B):64–73

    Article  PubMed  Google Scholar 

  31. Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291(1):47–53

    Article  PubMed  CAS  Google Scholar 

  32. McPherson K, Drife JO (1986) The pill and breast cancer: why the uncertainty? Br Med J (Clin Res Ed) 293(6549):709–710

    Article  CAS  Google Scholar 

  33. Malone KE, Daling JR, Weiss NS (1993) Oral contraceptives in relation to breast cancer. Epidemiol Rev 15(1):80–97

    PubMed  CAS  Google Scholar 

  34. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM (2007) The epidemiology of obesity. Gastroenterology 132(6):2087–2102

    Article  PubMed  Google Scholar 

  35. Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307(5):491–497

    Article  PubMed  Google Scholar 

  36. Shapiro S (1997) Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan. J Natl Cancer Inst Monogr 22:27–30

    PubMed  Google Scholar 

  37. Howard J (1987) Using mammography for cancer control: an unrealized potential. CA Cancer J Clin 37(1):33–48

    Article  PubMed  CAS  Google Scholar 

  38. Leads from the MMWR. Trends in screening mammograms for women 50 years of age and older—Behavioral Risk Factor Surveillance System, 1987. JAMA 261(14):2031–2032, (1989)

    Google Scholar 

  39. Glass AG, Hoover RN (1990) Rising incidence of breast cancer: relationship to stage and receptor status. J Natl Cancer Inst 82(8):693–696

    Article  PubMed  CAS  Google Scholar 

  40. Jonsson H, Johansson R, Lenner P (2005) Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer 117(5):842–847

    Article  PubMed  CAS  Google Scholar 

  41. Olsen AH, Jensen A, Njor SH, Villadsen E, Schwartz W, Vejborg I, Lynge E (2003) Breast cancer incidence after the start of mammography screening in Denmark. Br J Cancer 88(3):362–365

    Article  PubMed  CAS  Google Scholar 

  42. Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9(3):R28

    Article  PubMed  Google Scholar 

  43. Chen W, Hankinson S, Schnitt S, Rosner B, Holmes M, Colditz G (2004) Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 101:1490–1500

    Article  PubMed  CAS  Google Scholar 

  44. Fournier A, Fabre A, Mesrine S, Boutron-Ruault M, Berrino F, Clavel-Chapelon F (2008) Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 26:1260–1268

    Article  PubMed  Google Scholar 

  45. Bao P-P, Shu XO, Gao Y-T, Zheng Y, Cai H, Deming SL, Ruan Z-X, Su Y, Gu K, Lu W et al (2011) Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. Am J Epidemiol 174(6):661–671

    Article  PubMed  Google Scholar 

  46. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH (1985) A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 313(17):1044–1049

    Article  PubMed  CAS  Google Scholar 

  47. Ettinger B, Genant HK, Cann CE (1985) Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 102(3):319–324

    Article  PubMed  CAS  Google Scholar 

  48. Colditz GA (2007) Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res 9(4):108

    Article  PubMed  Google Scholar 

  49. Berry DA, Ravdin PM (2007) Breast cancer trends: a marriage between clinical trial evidence and epidemiology. J Natl Cancer Inst 99(15):1139–1141

    Article  PubMed  Google Scholar 

  50. National Center for Health Statistics (2005) Health, United States, 2005, with chartbook on trends in the health of Americans. Hyattsville

  51. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C (1996) Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 275(12):913–918

    Article  PubMed  CAS  Google Scholar 

  52. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674

    Article  PubMed  CAS  Google Scholar 

  53. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333

    Article  PubMed  CAS  Google Scholar 

  54. Writing Group for the Women’s Health Initiative I (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288(3):321–333

    Article  Google Scholar 

  55. Buist DS, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, Hartsfield CL, Wei F, Chan KA, Kessler L (2004) Hormone therapy prescribing patterns in the United States. Obstet Gynecol 104(5 Pt 1):1042–1050

    Article  PubMed  Google Scholar 

  56. Canfell K, Banks E, Moa AM, Beral V (2008) Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188(11):641–644

    PubMed  Google Scholar 

  57. Katalinic A, Rawal R (2008) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107(3):427–430

    Article  PubMed  CAS  Google Scholar 

  58. Soerjomataram I, Coebergh JW, Louwman MW, Visser O, van Leeuwen FE (2007) Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands? J Clin Oncol 25(31):5038–5039 author reply 5039-5040

    Article  PubMed  Google Scholar 

  59. De P, Neutel CI, Olivotto I, Morrison H (2010) Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst 102(19):1489–1495

    Article  PubMed  CAS  Google Scholar 

  60. Parkin DM (2009) Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer 45(9):1649–1653

    Article  PubMed  Google Scholar 

  61. Prasad R, Boland GP, Cramer A, Anderson E, Knox WF, Bundred NJ (2003) Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma. Cancer 98(12):2539–2546

    Article  PubMed  CAS  Google Scholar 

  62. DeSantis C, Howlader N, Cronin KA, Jemal A (2011) Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev 20(5):733–739

    Article  PubMed  Google Scholar 

  63. McNeil C (2007) Breast cancer decline mirrors fall in hormone use, spurs both debate and research. J Natl Cancer Inst 99(4):266–267

    Article  PubMed  Google Scholar 

  64. Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN (2010) Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 19(2):443–446

    Article  PubMed  CAS  Google Scholar 

  65. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE et al (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573–587

    Article  PubMed  CAS  Google Scholar 

  66. Buist DS, Walker R, Bowles EJ, Carney PA, Taplin SH, Onega T, Kerlikowske K, Clinton W, Miglioretti DL (2012) Screening mammography use among current, former, and never hormone therapy users may not explain recent declines in breast cancer incidence. Cancer Epidemiol Biomarkers Prev 21(5):720–727

    Article  PubMed  Google Scholar 

  67. Robbins AS, Clarke CA (2007) Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 25(23):3437–3439

    Article  PubMed  Google Scholar 

  68. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW (2003) Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 361(9367):1405–1410

    Article  PubMed  Google Scholar 

  69. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17):1784–1792

    Article  PubMed  CAS  Google Scholar 

  70. Kalager M, Haldorsen T, Bretthauer M, Hoff G, Thoresen SO, Adami HO (2009) Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study. Breast Cancer Res 11(4):R44

    Article  PubMed  Google Scholar 

  71. Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF (2006) Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr 36:30–36

    Article  PubMed  Google Scholar 

  72. Early Breast Cancer Trialists’ Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319(26):1681–1692

    Google Scholar 

  73. Independent UK Panel on Breast Cancer Screening (2012) The benefits and harms of breast cancer screening: an independent review. Lancet 380(9855):1778–1786

    Google Scholar 

  74. Botha JL, Bray F, Sankila R, Parkin DM (2003) Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 39(12):1718–1729

    Article  PubMed  CAS  Google Scholar 

  75. Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, La Vecchia C (2012) The decline in breast cancer mortality in Europe: an update (to 2009). Breast 21(1):77–82

    Article  PubMed  Google Scholar 

  76. Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, Hery C, Heanue M (2010) Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ 341:c3620

    Article  PubMed  Google Scholar 

  77. Bleyer A, Welch HG (2012) Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367(21):1998–2005

    Article  PubMed  CAS  Google Scholar 

  78. Glass AG, Lacey JV Jr, Carreon JD, Hoover RN (2007) Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99(15):1152–1161

    Article  PubMed  Google Scholar 

  79. Gilliland FD, Joste N, Stauber PM, Hunt WC, Rosenberg R, Redlich G, Key CR (2000) Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 92(9):743–749

    Article  PubMed  CAS  Google Scholar 

  80. Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J (2004) Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292(9):1064–1073

    Article  PubMed  CAS  Google Scholar 

  81. Esserman L, Shieh Y, Thompson I (2009) Rethinking screening for breast cancer and prostate cancer. JAMA 302(15):1685–1692

    Article  PubMed  CAS  Google Scholar 

  82. Winawer SJ, Zauber AG, Ho MN, MJ OB, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup [see comments]. N Engl J Med 329(27):1977–1981

    Article  PubMed  CAS  Google Scholar 

  83. Peto J, Gilham C, Fletcher O, Matthews FE (2004) The cervical cancer epidemic that screening has prevented in the UK. Lancet 364(9430):249–256

    Article  PubMed  Google Scholar 

  84. Jorgensen KJ, Gotzsche PC (2009) Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 339:b2587

    Article  PubMed  Google Scholar 

  85. Zahl PH, Gotzsche PC, Maehlen J (2011) Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol 12(12):1118–1124

    Article  PubMed  Google Scholar 

  86. Zahl PH, Maehlen J, Welch HG (2008) The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 168(21):2311–2316

    Article  PubMed  Google Scholar 

  87. Sainsbury R (2012) The development of endocrine therapy for women with breast cancer. Cancer Treat Rev (in press)

  88. Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716

    Article  PubMed  CAS  Google Scholar 

  89. Autier P, Boniol M, Gavin A, Vatten LJ (2011) Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 343:d4411

    Article  PubMed  Google Scholar 

  90. Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9(1):R6

    Article  PubMed  Google Scholar 

  91. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948

    Article  PubMed  CAS  Google Scholar 

  92. Anderson WF, Katki HA, Rosenberg PS (2011) Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 103(18):1397–1402

    Article  PubMed  Google Scholar 

  93. Jung S, Spiegelman D, Baglietto L, Bernstein L, Boggs DA, van den Brandt PA, Buring JE, Cerhan JR, Gaudet MM, Giles GG et al (2013) Fruit and vegetable intake and risk of breast cancer by hormone receptor status. J Natl Cancer Inst 105(3):219–236

    Google Scholar 

  94. Zhang X, Spiegelman D, Baglietto L, Bernstein L, Boggs DA, van den Brandt PA, Buring JE, Gapstur SM, Giles GG, Giovannucci E et al (2012) Carotenoid intakes and risk of breast cancer defined by estrogen receptor and progesterone receptor status: a pooled analysis of 18 prospective cohort studies. Am J Clin Nutr 95(3):713–725

    Article  PubMed  CAS  Google Scholar 

  95. Wu Y, Zhang D, Kang S (2013) Physical activity and risk of breast cancer: a meta-analysis of prospective studies. Breast Cancer Res Treat 137(3):869–882

    Article  PubMed  Google Scholar 

  96. Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ (2012) A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women’s Health Initiative. Menopause 19(6):616–621

    Article  PubMed  Google Scholar 

  97. Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, Huang AJ, Vitolins M, Hubbell FA, Manson JE et al (2011) Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst 103(7):562–570

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

There are no conflicts of interests.

Author information

Authors and Affiliations

  1. Division of Public Health Sciences, and Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8100, St. Louis, MO, 63110, USA

    Adetunji T. Toriola & Graham A. Colditz

Authors
  1. Adetunji T. Toriola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Graham A. Colditz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adetunji T. Toriola.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toriola, A.T., Colditz, G.A. Trends in breast cancer incidence and mortality in the United States: implications for prevention. Breast Cancer Res Treat 138, 665–673 (2013). https://doi.org/10.1007/s10549-013-2500-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-013-2500-7

Keywords

Search

Navigation